Viridian Therapeutics Financial Overview
Viridian Therapeutics's market cap is currently $3.07B. The company's EPS TTM is $-0.34; its P/E ratio is -8.94; Viridian Therapeutics is scheduled to report earnings on November 5, 2025, and the estimated EPS forecast is $-0.96. See an overview of income statement, balance sheet, and cash flow financials.
